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Abstract
Background: Adrenal suppression is a side effect of long‐term use of inhaled
corticosteroids (ICS). Hair cortisol concentration (HCC) measurement is a non-
invasive tool for measuring adrenal function that may be useful for asthmatic patients
who are on long‐term ICS treatment. The aim of this study was to compare HCC
between children with and without asthma and to explore the association between
HCC and ICS dose in asthmatic children.
Methods: A cross‐sectional observational study in subjects with or without asthma
(n = 72 and 226, respectively, age 6‐21 years). Hair samples were obtained from the
posterior vertex for each subject and data on medication use were collected using
questionnaires. HCC was analyzed by liquid chromatography‐mass spectrometry in
the most proximal 3 cm of hair.
Results:Median HCC was significantly lower in subjects with asthma than in subjects
without asthma: 1.83 pg/mg and 2.39 pg/mg, respectively (P value after adjustment
for age, sex, and body mass index: .036). Median HCC was 1.98 pg/mg in asthmatics
using no ICS, 1.84 pg/mg in those using a low dose, 1.75 pg/mg in those on a medium
dose, and 1.46 in those using a high ICS dose (P = .54).
Conclusion: We observed a significantly lower HCC in asthmatics than in healthy
controls and a nonsignificant trend of lower HCC with increasing ICS dose. Whether
HCC measurement may be used to detect individuals at risk for hypocortisolism and
may be useful to monitor adrenal function in asthmatic children using ICS needs to be
further investigated.
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1 | INTRODUCTION
Inhaled corticosteroids (ICS) are the first line of maintenance therapy
for asthma.1 ICS are regarded as safe, especially in lower dosages.2
However, some patients develop side effects and adrenal crisis has
been documented in children using ICS.3 The percentage of adrenal
suppression due to ICS use has been estimated to be around 8% and,
with a high ICS dose, up to 18%.4 Adrenal suppression due to ICS can
present with nonspecific symptoms including fatigue, anorexia,
abdominal pain and weight gain or loss, and often goes unrecognized.
Decreased growth can be a clinical sign of adrenal suppression, but
may also occur due to poor asthma control.5 Further complicating the
recognition of adrenal suppression is the fact that sensitivity to
glucocorticosteroids varies greatly between individuals, implicating
that there is no “safe dose.”4 Genes associated with steroid
sensitivity have been localized, but they cannot predict the individual
risk of adrenal insufficiency.6 As ICS are mostly used long term,
monitoring of adrenal function would seem appropriate but is not yet
recommended by current asthma treatment guidelines.1
Serum cortisol varies highly during the day and responds quickly
to stress factors such as pain or anxiety. Hence random serum
cortisol measurements are not suitable to assess adrenal function.
Cortisol measurement without adrenal stimulation may not be
sufficient to determine the dynamic adrenal response.7 The
adrenocorticotropic hormone stimulation test is still the gold
standard and evaluates the maximal response of the adrenal glands.
However, this is an invasive test that only informs about the status of
the hypothalamic‐pituitary‐adrenal axis at that specific moment.7,8
Hence, there is a need for a noninvasive test reflecting the effect of
long‐term use of ICS on adrenal function.
Hair cortisol concentration (HCC) has potential to serve this
purpose.9 HCC measurement is painless, noninvasive, and does not
require a specific timing, which makes it suitable for repeated
assessments in monitoring a pediatric population. Previous literature
has shown a strong intraindividual stability of HCC, especially
compared with other methods of cortisol measurement.10 HCC has
proven to be specific and sensitive for diagnosing clinical outcomes in
hypercortisolism, for example, in patients with Cushing’s disease.11
There are few studies investigating the association between HCC and
ICS, and these show conflicting results. However, sample sizes were
small with few patients taking high dose ICS while especially these
patients are at risk of adrenal insufficiency.12-14 In this cross‐
sectional observational study, we measured and compared HCC
between asthmatic and nonasthmatic children. Additionally, the
association between ICS dose and HCC was investigated.
2 | MATERIALS AND METHODS
2.1 | Study population
Asthmatic children treated with ICS were selected from the Integrated
Primary Care Information (IPCI) database, which contains general
practitioner (GP) records of around 1.7 million patients in 2017.15
Asthmatic patients were eligible if they were between 6 and 18 years old,
had doctor‐diagnosed asthma, were treated with ICS, and did not use
hydrocortisone therapy at the time of HCC measurement (other oral
corticosteroids were allowed). The GPs of eligible patients were asked to
recruit selected patients in the study. Healthy controls were part of a
cohort from a previous study on hair cortisol.16 Subjects for this cohort
were recruited from primary and secondary schools in the Netherlands
and among siblings of children attending a pediatric outpatient clinic.
They were eligible for inclusion if they were between 6 and 18 years old,
did not use glucocorticoids or other medication influencing glucocorticoid
metabolism at the time of HCC measurement or in the previous 3
months, and did not have a chronic disease. These children were invited
to take part in the study and received oral and written information.
2.2 | Hair sample collection and analysis
Approximately 100 to 150 hairs were cut from the posterior vertex of
the scalp as close to the scalp as possible. The hair sample was taped to a
piece of paper and stored at room temperature. The samples were sent
to the Department of Clinical Chemistry, Erasmus MC, Rotterdam, The
Netherlands. The samples were processed and analyzed as described
previously.13,17 The proximal 3 cm of hair were used for analyses. As hair
grows on average about 1 cm per month, 3 cm relates to the cortisol
production during the 3 months before hair sample collection.18 The hair
samples were weighed, cut into 1‐cm pieces and washed in LC‐MS grade
isopropanol for 2minutes. After solid phase extraction, hair cortisol was
quantified per milligram of hair by liquid chromatography‐tandem mass
spectrometry (LCMS) using a Xevo TQ‐S system (Waters Chromato-
graphy, Milford, MA).
2.3 | Clinical data including ICS use
Information on patient characteristics such as age, sex, asthma
control, comorbidities, medication use in the previous 3 months and
systemic corticosteroid use at any time was obtained from
questionnaires that were completed by all subjects on the same
day as the hair sample collection (the index date). As there were up
to 2 years between patient selection and hair sampling, some
patients had turned older than 18 years at the time of hair collection.
If information on ICS dose was missing, prescription data from
the IPCI database for the same period was used to complete dosage
information.
2.4 | Statistical analyses
ICS exposure was analyzed in two ways. Firstly, ICS dosage was
converted to budesonide equivalent doses (125 μg fluticasone =200μg
budesonide, 200 μg beclomethasone= 200 μg budesonide, 80 μg cicleso-
nide =200 μg budesonide, and 100 μg beclomethasone extra‐fine = 200
μg budesonide).19 Secondly, dosages were categorized as “high,”
“medium,” and “low”: low dose was defined as a daily budesonide
equivalent dose of less than 400μg, medium dose as 400 to 800 μg and
high dose as more than 800 μg, irrespective of age.19
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Statistical analyses were performed using RStudio version 1.1.442.
Body mass index (BMI) z scores adjusted for age and sex were calculated
based on the 1997 Dutch nationwide growth study and height z scores
were calculated according to the 2010 Dutch reference values, using
Growth Analyser (Growth Analyser BV; Rotterdam, the Netherlands).20,21
Missing data on height and/or weight was imputed using multiple
imputations. Asthma was categorized as uncontrolled for a score of less
than or equal to 19 in the Asthma Control Test (children≥12 years old)
or childhood Asthma Control Test (children< 12 years old).22,23 HCC was
log‐transformed to achieve normality. The influence of asthma and ICS
dose on HCC was investigated using a linear regression model with and
without adjustment for age, sex, and BMI z score, with the significance
level set at greater than .05. Differences in anthropometric measures
were tested using theWilcoxon signed‐rank test. To rule out the effect of
oral corticosteroids, analyses were repeated with exclusions of
asthmatics using oral corticosteroids in the 3 months before hair sample
collection.
2.5 | Ethical considerations
The protocol of this study was approved by the scientific review
committee of IPCI. The Medical Ethics Review Committee from the
Erasmus MC stated that the study did not fall within the remit of the
Medical Research Involving Human Subjects Act (WMO) (MEC‐2011‐
474). Written informed consent was obtained from all subjects and/
or parents or legal guardians.
3 | RESULTS
In total, 73 asthmatic and 226 nonasthmatic subjects were included in
the study. Median age was 13.2 years for asthmatics and 11.4 years for
nonasthmatics. In both cohorts more boys than girls were included (Table
1). The height z score was smaller in children with asthma than in the
healthy controls (median z score −0.3 vs 0.2, respectively, P< .001), Of all
asthmatic children, 20 (28%) had uncontrolled asthma based on the
(childhood) Asthma Control Test. One asthmatic child had an abnormally
high HCC (62 pg/mg). This patient was excluded from analysis as the
HCC was probably caused by inference due to the use of hydrocortisone
ointment. The HCC range completely overlapped between asthmatic and
nonasthmatic subjects. Median HCC was lower in asthmatic subjects
(1.83 pg/mg; interquartile range [IQR], 1.21‐3.04) than in nonasthmatic
subjects (2.39 pg/mg; IQR, 1.48‐3.78; P= .18). After adjustment for age,
sex, and BMI z score this difference was significant (P= .036). HCC
increased significantly with age (P< .0001), with and without adjustment
(Table 2).
In the 3 months before hair collection, 17 asthmatic subjects did
not use any ICS and 55 subjects used ICS in a median daily
budesonide equivalent dose of 500 μg. Of the subjects using ICS, 29
used a low dose, 22 a medium dose, and 4 a high dose.
With and without adjustment for age, sex, and BMI, budesonide
equivalent dose was not significantly associated with HCC in subjects
using ICS (regression coefficient [β] −.40 per mg budesonide; P = .26)
(Figure 1, Table 2). When categorizing ICS dose, median HCC was
1.98 pg/mg in the group using no ICS, 1.84 pg/mg in those using a low
ICS dose, 1.75 pg/mg in those on a medium dose, and 1.46 pg/mg in
those using a high ICS dose, but these differences were not
significant (β for increasing ICS dose category: −0.06; unadjusted
P = .58; adjusted for BMI z score, age, and sex: P = .54) (Figure 2).
Median HCC was higher in asthmatics not using ICS than in healthy
controls, this difference was not significant (P value after adjustment
for age, sex, and BMI z score: .15).
When analyzing HCC with the exclusion of asthmatics using oral
corticosteroids, results remained similar. After adjustment for age,
sex, and BMI, asthma was significantly associated with lower HCC.
HCC tended to decrease with increasing budesonide dose (β after
adjustment for age, sex, and BMI: −.41; P = .32). But there was no
correlation with increasing ICS dose category (β, −.06; P = .56).
Median HCC was 1.98 pg/mg in asthmatics using no ICS, 1.83 pg/mg
in those using a low dose, 1.77 pg/mg in those on a medium dose, and
1.46 pg/mg in those using a high ICS dose (Table 3).
4 | DISCUSSION
In this study, we showed that children with asthma have a significantly
lower HCC than children without asthma after adjustment for age, sex,
and BMI, but the HCC range completely overlapped between asthmatic
and nonasthmatic subjects. In addition, we observed a nonsignificant
trend of decreasing HCC with higher dosages of ICS.
TABLE 1 Demographics of study cohort at index date
Patients with
asthma (n = 72)
Healthy
controls
(n = 226)
Median age, y (IQR) 13.2 (10.5; 17.9) 12.6 (8.8; 14.8)
Females, n (%) 24 (33.3) 112 (49.6%)
Median height z score (IQR) −0.3 (1.2) 0.2 (1.2)
Missing, n 1 (0) 0 (0%)
Median BMI, z score (IQR) −0.5 (−1.0; 0.5) −0.1 (−0.6; 0.6)
Missing, n (%) 3 (4.2) 0 (0%)
Uncontrolled asthmaa, n (%) 20 (28) –
Medication use 3mo before
hair collection:
ICS use, n (%) 55 (76) –
Low doseb 29 (40) –
Medium doseb 22 (31) –
High doseb 4 (6) –
Budesonide equivalent use
(μg/d) (IQR)
500 (400; 1000) –
Oral corticosteroids use
(prednisone), n (%)
2 (2.8) –
Oral corticosteroids use
3‐6mo before hair
collection, n
1 (0) –
Abbreviations: BMI, body mass index; ICS, inhaled corticosteroids; IQR,
interquartile range.
aBased on the (childhood) Asthma Control Test.
bLow dose: less than 400 µg, medium dose: 400‐800 µg, high dose: greater
than 800 µg.
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Our data are consistent with a smaller prior study on HCC in 20
subjects which also observed a lower HCC in asthmatic children than
in nonasthmatic children. Medication was not analyzed in this
study.14 Smy et al observed an HCC reduction of about 50% after
ICS initiation in 18 asthmatic children. In a later study these authors
reported similar HCC in 407 asthmatic and 53 nonasthmatic children
0 to 18 years old.12,24 A difference between their and our study was
that Smy et al used an immunoassay to measure hair cortisol, and did
not adjust for confounders. Adjusting is important as we found that
HCC increased significantly with age. Other research groups have
shown that sex and BMI also influence HCC and as they are
associated with asthma, should be controlled for.25-27
In estimating the relationship between ICS use and HCC, the duration
of ICS use is an important aspect. Improvement of adrenal function 6 and
12 months after initiation of ICS therapy has been documented.28
However the actual risk of adrenal suppression is highest after years of
corticosteroid use.4 We measured the association between ICS and HCC
in chronic ICS users who had been using ICS for a period of at least 2
years. Like in our study, Smit et al13 investigated the effect of ICS dose on
HCC in a cross‐sectional design including 80 asthmatic children, and also
did not see a significant dose effect. We observed that the median HCC
TABLE 2 Results of linear regression analysis on log‐transformed hair cortisol concentration
Subjects Variable Univariate analyses, β (95% CI) P value Multivariable analyses, β (95% CI) P value
All subjects Asthma: yes −.15 (−0.37; 0.07) .18 −.24 (−0.46; −0.01) .04
Female sex −.11 (−0.30; 0.07) .23 −.15 (−0.33; 0.04) .12
Age, y .05 (0.03; 0.07) <.001 .05 (0.02; 0.07) <.001
BMI z score .13 (0.04; 0.22) .01 .08 (−0.01; 0.18) .09
Asthmatics using ICS Budesonide equivalent dose, mg −.29 (−0.95; 0.36) .58 −.40 (−1.09; 0.29) .26
Female sex .18 (−0.26; 0.62) .43 .07 (−0.41; 0.54) .79
Age, y .03 (−0.03; 0.08) .32 .03 (−0.03; 0.09) .31
BMI z score −.06 (−0.26; 0.14) .24 .09 (−0.10; 0.28) .34
All asthmatics Increasing ICS dose categorya −.06 (−0.26; 0.14) .58 −.06 (−0.27; 0.14) .54
Female sex .07 (−0.30; 0.44) .71 −.00 (−0.38; 0.38) .99
Age, y .03 (−0.01; 0.07) .18 .03 (−0.02; 0.07) .26
BMI z score .11 (−0.05; 0.27) .19 .09 (−0.07; 0.26) .28
Abbreviations: BMI, body mass index; CI, confidence interval; ICS, inhaled corticosteroids.
Bold values indicate P < .05.
aNo ICS, low dose ICS, medium dose ICS, high dose ICS.
F IGURE 1 Scatterplot of hair cortisol concentration by
budesonide equivalent dose in asthmatic subjects
F IGURE 2 Hair cortisol concentrations in ICS equivalent dose
categories dose in asthmatic subjects. ICS, inhaled corticosteroids
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was lower by increasing ICS dose categories (low, medium, and high) but
this difference in median HCC did not reach statistical significance
probably because of low numbers, especially of patients using high dose
ICS, and the variety in sensitivity to glucocorticosteroids. The median
HCC was even higher in asthmatic subjects not using ICS than in subjects
without asthma, though this difference was not significant.
ICS reaches the systemic circulation through two paths: absorption
from the lungs and absorption of swallowed drug. The part of the dose
that is absorbed through the gastrointestinal system will be considerably
reduced by hepatic first‐pass inactivation, probably resulting in smaller
systemic availability with poor inhalation technique.29 Systemic absorp-
tion of ICS is also age dependent. Studies have shown that the same ICS
dose in young children and adults, despite large differences in the dose
per kilogram bodyweight, leads to similar plasma concentrations.30,31
Global Initiative for Asthma guidelines use different dose categories for
children 6 to 12 years and from 12 years onward. In real life, the dose is
tailored to treatment response aiming for a balance between optimal
asthma control and minimal side effects. The Dutch asthma guidelines
recommend a starting dose of 200 μg budesonide twice daily, irrespective
of age.19 Therefore we used similar dose categories for all children.
Also, genes associated with an increased risk of adrenal
suppression in children using glucocorticosteroids have been
localized.6,32 Genotyping might further clarify the relation between
corticosteroids and adrenal function. However adrenal function tests
will still be needed when suspecting a case of adrenal insufficiency.
Our study has some limitations. Firstly, the number of patients
using ICS was limited. This affected power and precluded stratifying
for type of ICS and exploring the full dose range. Stratification would
have been interesting as different types of ICS might have a different
effect on the HPA axis.33 Because there was time between selection
of ICS users in the IPCI database and actual hair sample collection,
some subjects with asthma had stopped use ICS at the time of hair
sampling. Furthermore, medication use was based on questionnaire
data, which is prone to an overestimation of adherence.34 A strength
of our study is that we were able to adjust for sex, age, and BMI z
score as we know that they are associated with HCC levels.25
Another strength is that we used the LCMS method to measure HCC,
in contrast to an immunoassay which is more prone to interference
with synthetic corticosteroids. Immunoassays such as enzyme‐linked
immunosorbent assay are also known to be less sensitive and specific
for low cortisol concentrations than LCMS.35 And, importantly, we
investigated ICS doses as a continuous variable as well as categorical,
which made it possible to further characterize the effect of ICS. The
group with high dose ICS had the lowest median HCC, which is in line
with the fact that children taking a high dose ICS are most at risk for
adrenal insufficiency. This highlights again that they need to be
monitored regularly to screen for symptoms of systemic effects.
What is the clinical relevance of our findings?We have shown that on
a population level asthma is associated with a lower HCC when adjusting
for age, sex, and BMI. However, HCC values of asthmatic patients
overlapped with those of healthy controls, suggesting that they were still
within a normal range. Still, there was a tendency, although not
significant, for the HCC to decrease with increasing ICS dose. So
especially with high doses, it is important to be aware of possible
insufficient adrenal function. HCC measurement is a feasible, patient‐
friendly tool with potential to identify ICS‐treated individuals that are at
risk for adrenal insufficiency. We propose that future studies in children
with asthma on high dose ICS should include HCC as adrenal function
tests to see if hair cortisol measurement is a useful monitoring tool of
adrenal insufficiency on an individual level. There is a need to develop
reference ranges for HCC measured by LCMS in children aged 0 to 18
years, and the predictive value of different HCC cut‐off values for
developing adrenal insufficiency needs to be established.
To conclude, in this study we demonstrated that children with
asthma have lower HCC than children without asthma, possibly due
to adrenal suppression caused by ICS use. Whether HCC can be used
as a monitoring tool to predict the risk of hypocortisolism in children
with asthma needs to be further explored.
TABLE 3 Results of linear regression analysis on log‐transformed hair cortisol concentration after exclusion of patients using oral
corticosteroids
Subjects Variable Univariate analyses, β (95% CI) P value Multivariable analyses, β (95% CI) P value
All subjects Asthma: yes −.15 (−0.37; 0.07) .19 −.23 (−0.45;−0.01) .04
Female sex −.13 (−0.31; 0.05) .16 −.15 (−0.33; 0.04) .13
Age, y .05 (0.03; 0.07) <.0001 .05 (0.02; 0.07) <.001
BMI z score .13 (0.04; 0.22) .01 .08 (−0.01; 0.18) .10
Asthmatics using ICS Budesonide equivalent dose, mg −.29 (−0.97; 0.37) .40 −.41 (−1.1; 0.29) .32
Female sex .21 (−0.26; 0.67) .39 .01 (−0.38; 0.41) .96
Age, y .03 (−0.02; 0.09) .29 .03 (−0.02; 0.08) .21
BMI z score .11 (−0.07; 0.30) .25 .09 (−0.08; 0.26) .31
All asthmatics Increasing ICS dose categorya −.06 (−0.26; 0.15) .60 −.06 (−0.27; 0.15) .56
Female sex .08 (−0.30; 0.47) .68 .01 (−0.38; 0.41) .95
Age, y .03 (−0.01; 0.07) .16 .03 (−0.02; 0.07) .25
BMI z score .11 (−0.05; 0.27) .19 .09 (−0.87; 0.26) .30
Abbreviations: BMI, body mass index; CI, confidence interval; ICS; inhaled corticosteroids.
Bold values indicate P < .05.
aNo ICS, low dose ICS, medium dose ICS, high dose ICS.
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